We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Hims & Hers Advances AI-Powered Personalized Digital Healthcare
Read MoreHide Full Article
Key Takeaways
Hims & Hers is advancing AI, data infrastructure and personalization for tech-enabled healthcare delivery.
HIMS' new CTO and $870 million convertible notes back AI automation and individualized treatment tools.
Hims & Hers launches data-driven testosterone and menopause care tailored to patient-specific outcomes.
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is intensifying its use of artificial intelligence (AI), data infrastructure and personalization to power a next-generation healthcare experience. The company’s proprietary technology stack integrates electronic medical records, provider algorithms and real-time analytics to deliver individualized treatment pathways. This system enables adaptive recommendations, precise follow-ups and continuous refinement of care based on patient feedback and outcomes. By combining data-driven intelligence with clinical expertise, Hims & Hers transforms routine healthcare interactions into scalable, tech-enabled experiences that preserve human empathy while enhancing efficiency and accessibility.
Recent developments in 2025 underscore this strategic focus. The appointment of Mo Elshenawy as chief technology officer (CTO) marks a pivotal step toward AI-driven automation and intelligent diagnostics. Under his leadership, HIMS is advancing AI tools that seamlessly connect diagnosis, treatment and delivery — aligning with CEO Andrew Dudum’s vision of standardizing personalized, high-quality care at a global scale. In parallel, Hims & Hers’ $870 million convertible notes offering is designed to accelerate investment in data infrastructure and personalized treatment technologies.
These innovations are now reflected in new launches such as Hims’ personalized oral testosterone program and Hers’ menopause and perimenopause specialty, both of which leverage data-driven care models to tailor treatment to individual needs. By merging machine learning with patient data, Hims & Hers is building an intelligent healthcare ecosystem that enhances precision, affordability and access across its expanding wellness portfolio.
DOCS & AMWL’s AI-Driven Personalization and Hybrid Care Platforms
Doximity, Inc. (DOCS - Free Report) is deepening its use of AI and data to enhance clinical workflows. Doximity’s AI Scribe automates documentation while maintaining HIPAA compliance, and the 2025 acquisition of Pathway adds one of medicine’s largest structured datasets for precise, evidence-based answers. Together, these technologies personalize physician experiences, improve clinical accuracy and strengthen Doximity’s position as the leading digital platform for U.S. medical professionals. The integration of Pathway’s corpus into Doximity GPT further accelerates real-time, AI-informed decision support at the point of care.
American Well Corporation (AMWL - Free Report) , popularly known as Amwell, integrates AI and data analytics within its Converge platform to deliver personalized, efficient hybrid care. Its technology enhances clinical decision-making, automates workflows and adapts treatment pathways in real time for patients across major health systems and payers. In 2025, Amwell expanded AI-driven automation and care personalization, solidifying its role as a data-powered digital backbone for modern, scalable healthcare delivery. Amwell’s AI-enabled tools also support the U.S. Military Health System, improving access, efficiency and continuity of care for millions.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 104.1% year to date, outperforming the industry’s growth of 28.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 4.1X is lower than the industry’s average of 5.9X, but is higher than its three-year median of 2.5X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 118.5% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
Image: Bigstock
Hims & Hers Advances AI-Powered Personalized Digital Healthcare
Key Takeaways
The renowned health and wellness platform, Hims & Hers Health, Inc. (HIMS - Free Report) , is intensifying its use of artificial intelligence (AI), data infrastructure and personalization to power a next-generation healthcare experience. The company’s proprietary technology stack integrates electronic medical records, provider algorithms and real-time analytics to deliver individualized treatment pathways. This system enables adaptive recommendations, precise follow-ups and continuous refinement of care based on patient feedback and outcomes. By combining data-driven intelligence with clinical expertise, Hims & Hers transforms routine healthcare interactions into scalable, tech-enabled experiences that preserve human empathy while enhancing efficiency and accessibility.
Recent developments in 2025 underscore this strategic focus. The appointment of Mo Elshenawy as chief technology officer (CTO) marks a pivotal step toward AI-driven automation and intelligent diagnostics. Under his leadership, HIMS is advancing AI tools that seamlessly connect diagnosis, treatment and delivery — aligning with CEO Andrew Dudum’s vision of standardizing personalized, high-quality care at a global scale. In parallel, Hims & Hers’ $870 million convertible notes offering is designed to accelerate investment in data infrastructure and personalized treatment technologies.
These innovations are now reflected in new launches such as Hims’ personalized oral testosterone program and Hers’ menopause and perimenopause specialty, both of which leverage data-driven care models to tailor treatment to individual needs. By merging machine learning with patient data, Hims & Hers is building an intelligent healthcare ecosystem that enhances precision, affordability and access across its expanding wellness portfolio.
DOCS & AMWL’s AI-Driven Personalization and Hybrid Care Platforms
Doximity, Inc. (DOCS - Free Report) is deepening its use of AI and data to enhance clinical workflows. Doximity’s AI Scribe automates documentation while maintaining HIPAA compliance, and the 2025 acquisition of Pathway adds one of medicine’s largest structured datasets for precise, evidence-based answers. Together, these technologies personalize physician experiences, improve clinical accuracy and strengthen Doximity’s position as the leading digital platform for U.S. medical professionals. The integration of Pathway’s corpus into Doximity GPT further accelerates real-time, AI-informed decision support at the point of care.
American Well Corporation (AMWL - Free Report) , popularly known as Amwell, integrates AI and data analytics within its Converge platform to deliver personalized, efficient hybrid care. Its technology enhances clinical decision-making, automates workflows and adapts treatment pathways in real time for patients across major health systems and payers. In 2025, Amwell expanded AI-driven automation and care personalization, solidifying its role as a data-powered digital backbone for modern, scalable healthcare delivery. Amwell’s AI-enabled tools also support the U.S. Military Health System, improving access, efficiency and continuity of care for millions.
HIMS’ Price Performance, Valuation and Estimates
Shares of Hims & Hers have gained 104.1% year to date, outperforming the industry’s growth of 28.2%.
Image Source: Zacks Investment Research
HIMS’ forward 12-month P/S of 4.1X is lower than the industry’s average of 5.9X, but is higher than its three-year median of 2.5X. It carries a Value Score of D.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for HIMS’ 2025 earnings per share suggests a 118.5% improvement from 2024.
Image Source: Zacks Investment Research
Hims & Hers currently carries a Zacks Rank #3 (Hold).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.